Abstract:Famotidine is an H2 receptor antagonist belonging to the BCS Class II, characterized by low solubility and limited oral bioavailability. The current study encompasses the formulation of novel famotidine phospholipid complex (FHC) with the aid of design of experiments (Central Composite Design) using solvent evaporation technique to overcome the disadvantages of Famotidine. To further enhance the physicochemical properties of FHC, it was incorporated into gastro-retentive floating tablets (GRDDS) using direct compression technique with sodium bicarbonate as a gas generating agent and its properties were compared to famotidine floating tablets. The pre-compression parameters, namely bulk density, tapped density, Hausner’s ratio, Carr’s compressibility index and angle of repose were evaluated. The flow properties of FHC granules were found to be better than the plain famotidine granules. The postcompression parameters, namely thickness, hardness, friability, weight variation, drug content and swelling index showed better results for FHC as compared to famotidine floating tablets. In-vitro buoyancy study indicated that the floating lag time for FHC tablets (110 ± 0.021 seconds) was higher than famotidine tablets (36 ± 0.033 seconds) owing to the higher molecular weight of phosphatidylcholine. But the total floating time for FHC tablets was found to be more than 18 hours and for famotidine tablets it was ~12 hours, indicating the improved residence time and buoyancy. The in-vitro dissolution study depicted that the cumulative release for FHC tablets (99.84 ± 0.058%) was enhanced 1.07 fold than Famotidine tablets (92.73 ± 0.028%) and 1.6 fold than marketed tablet, Famocid (62.24 ± 0.023%). When kinetic modeling was performed, famotidine tablet followed zero order kinetics, whereas FHC tablet followed Higuchi model indicating a modified and sustained release pattern. The statistical analysis for %cumulative release performed using ANOVA and Dunnett’s test showed the p-value to be below 0.05 (0.0043) indicating that the analysis model was significant. An accelerated stability study was performed for a period of 6 months at 25 ± 2°C; 60 ± 5% RH. FHC tablets showed a better stability profile than famotidine tablets. In conclusion, FHC gastro-retentive floating tablets showed improved flow properties, post compression properties, better drug content, improved in-vitro buoyancy and enhanced cumulative release and stability profile.

Pharmacokinetic Study of Ranitidine Hydrochloride Remaining-Floating Sustained Release Tablet in Stomach

Development, optimization, and in vitro/in vivo evaluation of ranitidine hydrochloride resinate sustained release suspension

Design, development and optimization of sustained release floating, bioadhesive and swellable matrix tablet of ranitidine hydrochloride

Study on pramipexole dihydrochloride sustained-release tablets

Study on Correlation Between in vitro Release and in vivo Absorption of Captopril Delayed-onset, Sustained Release Tablet

Preparation and in Vitro Release Study of Sodium Ferulate Gastric Floating Tablets

[Preparation of the 5-Fu Floating Sustained Release Tablet for Gastric Retention].

DDSolver Software Application for Quantitative Analysis of In vitro Drug Release Behavior of the Gastroretentive Floating Tablets Combined with Radiological Study in Rabbits

Gastro-floating tablets of cephalexin: preparation and in vitro/in vivo evaluation.

Review of endoscopic ultrasound‐guided fine‐needle aspiration cytology

Preparation, optimization and in vivo study of gastric floating tablets of constunolide and dehydrocostus lactone with ideal therapeutic effect on gastric diseases

Preparation of Sustained-Release Tetramethylpyrazine Phosphate Tablet and its Bioavailability on Rabbits

Formulation and Evaluation of Gastro-retentive Drug Delivery System of Novel Famotidine Phospholipid Complex

Effervescent and standard formulations of ranitidine--a comparison of their pharmacokinetics and pharmacology

Preparation and phamacokinetics of sustained-release dosage form of naproxen sodium

In Vitro Release Characteristic of Famotidine Bioadhesive Sustained-Release Tablets

Design, preparation, and in vitro evaluation of gastroretentive floating matrix tablet of mitiglinide

MRI of pelvic masses: Efficacy of the rectal superparamagnetic contrast agent ferumoxsil

In Vitro Dissolution of Ranolazine Sustained-Release Tablets

Development of Sustained Release System Based on High Water-Absorbable Gel Formation Using Croscarmellose Sodium, Alkaline Excipients and HPMC (ACSH SR System); Novel Application of Croscarmellose Sodium as a Gel Former

DEVELOPMENT OF GASTRORETENTIVE MUCOADHESIVE SOLID DOSAGES FORM CONTAINING AMOXICILLIN TRIHYDRATE AND RANITIDINE HCL FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTIONS